AR003974A1 - A NEW MP52 ARG HUMAN PROTEIN, A PROCESS FOR THE PRODUCTION AND ISOLATION OF THE SAME AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT - Google Patents
A NEW MP52 ARG HUMAN PROTEIN, A PROCESS FOR THE PRODUCTION AND ISOLATION OF THE SAME AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN ITInfo
- Publication number
- AR003974A1 AR003974A1 ARP960103838A AR10383896A AR003974A1 AR 003974 A1 AR003974 A1 AR 003974A1 AR P960103838 A ARP960103838 A AR P960103838A AR 10383896 A AR10383896 A AR 10383896A AR 003974 A1 AR003974 A1 AR 003974A1
- Authority
- AR
- Argentina
- Prior art keywords
- bone
- isolation
- production
- arg
- contain
- Prior art date
Links
- 101100472152 Trypanosoma brucei brucei (strain 927/4 GUTat10.1) REL1 gene Proteins 0.000 title abstract 3
- 238000002955 isolation Methods 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000010392 Bone Fractures Diseases 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 230000004097 bone metabolism Effects 0.000 abstract 1
- 230000034127 bone morphogenesis Effects 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000399 orthopedic effect Effects 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Compuesto de MP52 Arg humana y composición medicinal farmacéutica que lo comprende para promover entre otros la morfogenésis cartilaginosa y ósea,composición farmacéutica que comprende MP52 Arg humano. En particular, la composiciónmedicinal es útil para tratar enfermedades óseas causadas pormetabolismo óseo anormal, tales como osteoporosis, para tratar fracturas óseas y para el propósito de reconstrucción ortopédica, transplante óseo,cirugía cosmética y terapéuticadental. Asimi smo, es útil para tratar desórdenes cartilaginosos. La invención también se refiere a un proceso parala producción y aislación de una proteína biológicamente activa, en el cual al menos una parte de la secuencia de DNA de lainvención es i ntroducida dentro deuna célula huesped adecuada bajo condiciones adecuadas.Composed of human MP52 Arg and pharmaceutical medicinal composition comprising it to promote, among others, cartilaginous and bone morphogenesis, pharmaceutical composition comprising human MP52 Arg. In particular, the medicinal composition is useful for treating bone diseases caused by abnormal bone metabolism, such as osteoporosis, for treating bone fractures and for the purpose of orthopedic reconstruction, bone transplantation, cosmetic and dental therapeutic surgery. Furthermore, it is useful for treating cartilaginous disorders. The invention also relates to a process for the production and isolation of a biologically active protein, in which at least a part of the DNA sequence of the invention is introduced into a suitable host cell under suitable conditions.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95112241 | 1995-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR003974A1 true AR003974A1 (en) | 1998-09-30 |
Family
ID=8219499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960103838A AR003974A1 (en) | 1995-08-03 | 1996-08-01 | A NEW MP52 ARG HUMAN PROTEIN, A PROCESS FOR THE PRODUCTION AND ISOLATION OF THE SAME AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0842274A1 (en) |
| JP (1) | JP2000511155A (en) |
| KR (1) | KR19990036081A (en) |
| CN (1) | CN1192237A (en) |
| AR (1) | AR003974A1 (en) |
| AU (1) | AU699708B2 (en) |
| BR (1) | BR9609983A (en) |
| CA (1) | CA2227204A1 (en) |
| HU (1) | HUP9900362A2 (en) |
| IL (1) | IL122817A0 (en) |
| MX (1) | MX9800801A (en) |
| NO (1) | NO980375D0 (en) |
| PL (1) | PL324822A1 (en) |
| WO (1) | WO1997006254A1 (en) |
| ZA (1) | ZA966489B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6586388B2 (en) | 1988-04-08 | 2003-07-01 | Stryker Corporation | Method of using recombinant osteogenic protein to repair bone or cartilage defects |
| GB9610281D0 (en) * | 1996-05-16 | 1996-07-24 | Ralston Stuart H | Diagnostic method and apparatus |
| DE19906096A1 (en) | 1999-02-13 | 2000-08-17 | Walter Sebald | Protein with a heparin-binding epitope |
| US20130122066A1 (en) | 2010-07-30 | 2013-05-16 | Biopham Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Drug delivery devices and growth factor formulations for accelerated wound healing |
| EP2537538A1 (en) | 2011-06-22 | 2012-12-26 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH | Bioresorbable Wound Dressing |
| EP2602264A1 (en) | 2011-12-05 | 2013-06-12 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH | GDF-5 mutant for inducing cartilage formation |
| KR101213355B1 (en) * | 2011-12-27 | 2012-12-18 | 오스템임플란트 주식회사 | Dental implant improving initial stability and the method for manufacturing the same |
| WO2021122545A1 (en) | 2019-12-18 | 2021-06-24 | Merck Patent Gmbh | Use of the gdf-5 mutant for the treatment of pain and cartilage destruction |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE188996T1 (en) * | 1992-02-12 | 2000-02-15 | Bioph Biotech Entw Pharm Gmbh | DNA SEQUENCES CODING FOR NOVEL GROWTH/DIFERENTATION FACTORS |
| DE4420157B4 (en) * | 1993-08-10 | 2013-04-25 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | New growth / differentiation factor of the TGF-β family |
| IL110589A0 (en) * | 1993-08-10 | 1994-11-11 | Bioph Biotech Entw Pharm Gmbh | Growth/differentiation factor of the TGF- beta family |
| DE69434651T2 (en) * | 1993-12-07 | 2007-03-08 | Genetics Institute, Inc., Cambridge | BMP-12, BMP-13 AND THESE INCLUDING SEWNE-INDUCTIVE COMPOSITIONS |
-
1996
- 1996-07-31 ZA ZA9606489A patent/ZA966489B/en unknown
- 1996-08-01 AR ARP960103838A patent/AR003974A1/en not_active Application Discontinuation
- 1996-08-02 PL PL96324822A patent/PL324822A1/en unknown
- 1996-08-02 AU AU67891/96A patent/AU699708B2/en not_active Ceased
- 1996-08-02 KR KR1019980700747A patent/KR19990036081A/en not_active Withdrawn
- 1996-08-02 CN CN96195841A patent/CN1192237A/en active Pending
- 1996-08-02 JP JP09508115A patent/JP2000511155A/en active Pending
- 1996-08-02 EP EP96928406A patent/EP0842274A1/en not_active Withdrawn
- 1996-08-02 HU HU9900362A patent/HUP9900362A2/en unknown
- 1996-08-02 BR BR9609983A patent/BR9609983A/en not_active Application Discontinuation
- 1996-08-02 CA CA002227204A patent/CA2227204A1/en not_active Abandoned
- 1996-08-02 IL IL12281796A patent/IL122817A0/en unknown
- 1996-08-02 WO PCT/EP1996/003427 patent/WO1997006254A1/en not_active Ceased
-
1998
- 1998-01-28 MX MX9800801A patent/MX9800801A/en unknown
- 1998-01-28 NO NO980375A patent/NO980375D0/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000511155A (en) | 2000-08-29 |
| ZA966489B (en) | 1997-02-26 |
| NO980375L (en) | 1998-01-28 |
| CA2227204A1 (en) | 1997-02-20 |
| AU6789196A (en) | 1997-03-05 |
| MX9800801A (en) | 1998-11-29 |
| NO980375D0 (en) | 1998-01-28 |
| AU699708B2 (en) | 1998-12-10 |
| IL122817A0 (en) | 1998-08-16 |
| WO1997006254A1 (en) | 1997-02-20 |
| BR9609983A (en) | 1999-01-12 |
| KR19990036081A (en) | 1999-05-25 |
| EP0842274A1 (en) | 1998-05-20 |
| CN1192237A (en) | 1998-09-02 |
| PL324822A1 (en) | 1998-06-22 |
| HUP9900362A2 (en) | 1999-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA42747C2 (en) | PEPTIDE DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHOD FOR STIMULATING GROWTH HORMONE SECRETION | |
| ES2156421T3 (en) | USEFUL COMPOSITIONS FOR THE TRANSFER OF THERAPEUTICALLY ACTIVE POLINUCLEOTIDES TO A DAILY CELL AND ITS USE IN GENE THERAPY. | |
| YU18400A (en) | Prostaglandin agonists and their use to treat bone disorders | |
| DE3851776D1 (en) | Use of IGF-II for the treatment of bone diseases. | |
| BR0210374A (en) | Heteroarylsulfonyl side chain anthranilic acid amides, processes for producing them, use thereof as a medicine or diagnostic agent, as well as pharmaceutical preparations containing them | |
| MXPA06000660A (en) | Use of a cosmetic or pharmaceutical composition, comprising a lupeol-rich extract as an active ingredient for stimulating the synthesis of heat shock proteins. | |
| ES2039209T5 (en) | PHARMACEUTICAL COMPOUND THAT PROMOTES THE RESTORATION OF HEMOPOYETIC CAPACITY. | |
| MXPA03000406A (en) | USE OF 2-METHYLENE-19-NOR-20(S)-1agr;,25-DIHYDROXYVITAMIN D3. | |
| AR003974A1 (en) | A NEW MP52 ARG HUMAN PROTEIN, A PROCESS FOR THE PRODUCTION AND ISOLATION OF THE SAME AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT | |
| NZ328874A (en) | Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders | |
| Tanjaya et al. | The effects of systemic therapy of PEGylated NEL-like protein 1 (NELL-1) on fracture healing in mice | |
| US6270750B1 (en) | Proline-, glycine- and lysine-based pharmaceutical composition useful in dental treatment both in the injectable form and in the formulation for topical use | |
| ES2616004T3 (en) | Prophylactic agent and / or therapeutic agent and / or exacerbating suppressing agent for human knee osteortritis | |
| ES2110057T3 (en) | MEDICINAL COMPOSITION CONTAINING TCF-II. | |
| US20150335660A1 (en) | Formulation for Regeneration of Bone, Cartilage, Teeth, and Periodontium and Treatment of Tumors and Cysts | |
| DE4240713C1 (en) | Calcium hydroxide and oleum pedum tauri mixture - opt. also contains barium sulphate and vaseline end can be used to promote collagen formation in healing bones | |
| WO2018038966A1 (en) | Pharmaceutical compositions for inducing phenotypic reversion of a cell and regeneration of compromised tissue | |
| Grangeat et al. | Inflammatory Mechanisms Involved in the Lumbar Disc Herniation with Hydrated Nucleus Pulposus (Acute Herniated Disc) and the Oxygen-Ozone Therapy A Different Viewpoint. | |
| RU2147236C1 (en) | Method for stimulating reparative osteogenesis | |
| EP3145514B1 (en) | Formulation for regeneration of bone and cartilage | |
| JPH07258110A (en) | Agent for treatment of bone disease | |
| EP1502593B1 (en) | The use of Stanozolol for the preparation of anti-inflammatory and anti-degenerative drugs | |
| RU2241473C2 (en) | Gel "stopartros" for prophylaxis and treatment of degenerative-dystrophic injure of articular cartilage and intervertebral disk and method for its preparing | |
| DE102024110866A1 (en) | Pharmaceutical composition for healing a wound | |
| RU2511737C2 (en) | Method for preparing platelet-rich plasma to be used as ingredient of ointment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |